The estimated Net Worth of Angela L Wirick is at least $4.44 millió dollars as of 1 March 2024. Ms. Wirick owns over 5,000 units of Atricure Inc stock worth over $3,740,983 and over the last 4 years she sold ATRC stock worth over $697,707. In addition, she makes $0 as Chief Financial Officer at Atricure Inc.
Angela has made over 3 trades of the Atricure Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 5,000 units of ATRC stock worth $84,750 on 1 March 2024.
The largest trade she's ever made was selling 5,939 units of Atricure Inc stock on 6 August 2021 worth over $476,367. On average, Angela trades about 1,231 units every 85 days since 2020. As of 1 March 2024 she still owns at least 139,070 units of Atricure Inc stock.
You can see the complete history of Ms. Wirick stock trades at the bottom of the page.
Angela L. Wirick serves as Chief Financial Officer of the Company. Since March 2016, Ms. Wirick has served as the Company’s Vice President, Finance. She joined the Company in July 2014 as the Company’s Director, Finance. Prior to joining AtriCure, Ms. Wirick, a certified public accountant, was employed by Deloitte & Touche LLP for twelve years where she held positions of increasing responsibility.
Angela's mailing address filed with the SEC is 7555, Innovation Way, Innovation Business Center, Mason, Warren County, Ohio, 45040, United States.
Over the last 19 years, insiders at Atricure Inc have traded over $52,789,242 worth of Atricure Inc stock and bought 666,621 units worth $5,937,195 . The most active insiders traders include Scott William Drake, Group I, Llc Donoghue Danie... és Management Group Viii L L C.... On average, Atricure Inc executives and independent directors trade stock every 24 days with the average trade being worth of $548,410. The most recent stock trade was executed by Maggie Yuen on 15 August 2024, trading 3,500 units of ATRC stock currently worth $84,245.
atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.
Atricure Inc executives and other stock owners filed with the SEC include: